Overcoming Resistance to Targeted Therapies in EGFR-Positive Patients
laurabbook@gmail.com2019-02-11T13:17:42+00:00*January 29, 2019* Lungevity, by Juhi Kunde. In 2004, after the discovery of mutations in the EGFR gene in lung
3
February 2019
3
February 2019
A cancer researcher reflects on the evolution of lung cancer therapies
laurabbook@gmail.com2019-02-03T11:20:23+00:00*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons. When Dr. Lecia Sequist was undergoing her training to
3
February 2019
Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC
laurabbook@gmail.com2019-02-03T11:06:16+00:00*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had
5
January 2019
OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?
laurabbook@gmail.com2019-01-05T11:08:03+00:00*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer.
4
January 2019
Study Shows Key Enzyme Linked to Therapy Resistance in Deadly Lung Cancer
laurabbook@gmail.com2019-01-05T11:18:38+00:00*December 10, 2018, University of Texas M. D. Anderson Cancer Center* Researchers at The University of Texas MD Anderson Cancer Center
4
January 2019
Cancer Research UK Tests First of its Kind Vaccine to Treat Lung Cancer
laurabbook@gmail.com2019-01-04T18:45:14+00:00June 12 2018. A first of its kind treatment vaccine has moved into a phase I clinical trial for patients
22
November 2018
PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS
laurabbook@gmail.com2018-11-22T13:19:38+00:00Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer
22
November 2018
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
laurabbook@gmail.com2018-11-22T12:55:52+00:00*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains
22
November 2018
J&J buys novel lung cancer drug from South Korea’s Yuhan
laurabbook@gmail.com2018-11-22T12:43:11+00:00*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with